Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose ; volume:24 ; number:1 ; day:20 ; month:1 ; year:2024 ; pages:1-9 ; date:12.2024
Clinical and experimental medicine ; 24, Heft 1 (20.1.2024), 1-9, 12.2024
- Urheber
-
Sanna, Giuseppina
Marongiu, Alessandra
Firinu, Davide
Piras, Cristina
Palmas, Vanessa
Galdiero, Massimiliano
Atzori, Luigi
Caria, Paola
Campagna, Marcello
Perra, Andrea
Costanzo, Giulia
Coghe, Ferdinando
Littera, Roberto
Chessa, Luchino
Manzin, Aldo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10238-023-01276-x
- URN
-
urn:nbn:de:101:1-2024033121560733050311
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sanna, Giuseppina
- Marongiu, Alessandra
- Firinu, Davide
- Piras, Cristina
- Palmas, Vanessa
- Galdiero, Massimiliano
- Atzori, Luigi
- Caria, Paola
- Campagna, Marcello
- Perra, Andrea
- Costanzo, Giulia
- Coghe, Ferdinando
- Littera, Roberto
- Chessa, Luchino
- Manzin, Aldo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents